2-hydroxy-2-methyl-2-(4'-methylphenyl)acetonitrile | 69813-74-7

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-2-methyl-2-(4'-methylphenyl)acetonitrile
• 英文别名: 4-methylacetophenone cyanohydrin；p-Methyl-acetophenon-cyanhydrin；2-hydroxy-2-(4-methylphenyl)propanenitrile；2-hydroxy-2-p-tolyl-propionitrile
• CAS: 69813-74-7
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: QXZNUYRVNFFGBA-UHFFFAOYSA-N

物化性质

• 熔点：
  78-80 °C
• 沸点：
  308.8±27.0 °C(Predicted)
• 密度：
  1.098±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-hydroxy-2-methyl-2-(4'-methylphenyl)acetonitrile 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 以90%的产率得到α-tolyl-α-hydroxypropionic acid
  参考文献：
  名称：

  通过HI水溶液处理从氰醇中方便地一锅制备2-芳基丙酸和芳酸

  摘要：

  已开发出一种新颖的一锅两步法，通过用氰化醇中的HI水溶液处理，可以合成高度取代的2-芳基丙酸和芳酸。α-羟基-2-芳基丙酸的氢解还原是该工艺的关键步骤，反应条件的优化确定了HI水溶液是氰醇还原性脱氧的合适和选择性试剂。合成路线描述了制备苯乙酸和苯丙酸衍生物的大型文库的通用有效策略。

  DOI：

  10.1016/j.tet.2009.01.005
• 作为产物：
  描述：

  4-乙基甲苯 在 水 、 氧气 、 [Hf6(μ₃-O)₄(μ₃-OH)₄(OTf)₆(4'-(4-carboxyphenyl)[2,2':6',2''-terpyridine]-5,5''-dicarboxylic acid-FeOTf₂)₂] 、 silica gel 作用下， 以 正己烷 、 乙酸乙酯 、 1,2-二氯乙烷 为溶剂， -78.0~20.0 ℃ 、100.0 kPa 条件下， 反应 60.0h， 生成 2-hydroxy-2-methyl-2-(4'-methylphenyl)acetonitrile
  参考文献：
  名称：

  Bifunctional Metal–Organic Layers for Tandem Catalytic Transformations Using Molecular Oxygen and Carbon Dioxide

  摘要：

  DOI：

  10.1021/jacs.1c07963

文献信息

• Cyano-borrowing reaction: nickel-catalyzed direct conversion of cyanohydrins and aldehydes/ketones to β-cyano ketone
  作者：Zhao-Feng Li、Qian Li、Li-Qing Ren、Qing-Hua Li、Yun-Gui Peng、Tang-Lin Liu

  DOI：10.1039/c9sc00640k

  日期：——

  nickel-catalyzed, high atom- and step-economical reaction of cyanohydrins with aldehydes or ketones via an unprecedented “cyano-borrowing reaction” has been developed. Cleavage of the C–CN bond of cyanohydrins followed by aldol condensation and conjugate addition of cyanide to α,β-unsaturated ketones proceeded to deliver a range of racemic β-cyano ketones with good to high yields. The practical procedure

  通过前所未有的“借氰反应” ，氰醇与醛或酮的直接镍催化、高原子和多步经济的反应已被开发出来。氰醇的 C-CN 键断裂，然后是羟醛缩合和氰化物与 α,β-不饱和酮的共轭加成，以良好至高产率提供一系列外消旋 β-氰基酮。使用商业和毒性较低的 CN 源的实际程序预示着该协议的广泛应用。
• Titanium-Catalyzed Cyano-Borrowing Reaction for the Direct Amination of Cyanohydrins with Ammonia
  作者：Qing-Hua Li、Zhao-Feng Li、Jing Tao、Wan-Fang Li、Li-Qing Ren、Qian Li、Yun-Gui Peng、Tang-Lin Liu

  DOI：10.1021/acs.orglett.9b03194

  日期：2019.10.18

  intermedia in organic chemistry. Herein, the direct amination of cyanohydrins with the partner of ammonia to synthesis N-unprotected α-aminonitriles is developed. The reaction proceeds via titanium-catalyzed cyano-borrowing reaction, which features high atom economy and simple operation. A broad range of ketone or aldehyde cyanohydrins was tolerated with ammonia, and the N-unprotected α-aminonitriles were

  α-氨基腈是天然产物中的重要组成部分，也是有机化学中的重要中间介质。本文中，开发了氰醇与氨的伙伴直接胺化以合成N-未保护的α-氨基腈。该反应通过钛催化的氰基借位反应进行，该反应具有较高的原子经济性和操作简单的特点。氨可耐受各种酮或醛氰醇，并且在温和的反应条件下以中等至高收率合成了N-未保护的α-氨基腈。
• Facile Synthesis and In-Vitro Antimalarial Activity of Novel α-Hydroxy Hydrazonates
  作者：Mehdi Khankischpur、Finn K. Hansen、Ronald Meurer、Tobias Mauz、Baerbel Bergmann、Rolf D. Walter、Detlef Geffken

  DOI：10.1002/ardp.201000346

  日期：2011.11

  A series of previously unreported α‐hydroxy hydrazonates were synthesized and tested for their antimalarial properties. Structure optimization of the antiplasmodially active α‐hydroxy hydrazonate III furnished derivatives with strong in‐vitro antimalarial activity against 3D7 strains of Plasmodium falciparum with IC50 values lower than 2.0 µM.

  合成了一系列以前未报道的 α-羟基腙，并测试了它们的抗疟特性。抗疟原虫活性α-羟基腙III的结构优化提供了对恶性疟原虫3D7菌株具有强体外抗疟活性的衍生物，IC50值低于2.0 µM。
• (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS
  申请人：Iwema Bakker Wouter I.

  公开号：US20120220552A1

  公开（公告）日：2012-08-30

  The present disclosure relates to (thio)morpholine derivatives of the formula (I) wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino, —SO 2 -(1-4C)alkyl, —CO-(1-4C)alkyl, —CO—O-(1-4C)alkyl, —NH—CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from —CO—O—, —O—CO—, —NH—CO—, —CO—NH, —C═C—, —CCH 3 —O— and the linking group —Y—(CH 2 ) n —X— wherein Y is attached to R1 and selected from a bond, —O—, —S—, —SO—, —SO 2 —, —CH 2 —O—, —CO—, —O—CO—, —CO—O—, —CO—NH—, —NH—CO—, —C═C— and —C≡C—; n is an integer from 1 to 10; and X is attached to the phenylene/pyridyl group and selected from a bond, —O—, —S—, —SO—, —SO 2 —, —NH, —CO—, —C═C— and —C≡C—; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH 2 ) 2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is (3-6C)cycloalkylene-R5 or —CO—CH 2 —R5, wherein R5 is —OH, —PO 3 H 2 , —OPO 3 H 2 , —COOH, —COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is —O—, —S—, —SO— or —SO 2 —; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the disclosure have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本公开涉及以下式子的(硫)吗啡啶衍生物(I)： 其中，R1从氰基，(2-4C)炔基，(1-4C)烷基，(3-6C)环烷基，(4-6C)环烯基，(6-8C)双环烷基，(8-10C)双环基中选择，每个基都可以选择性地被(1-4C)烷基，苯基，联苯基，萘基取代，每个基也可以选择性地被一个或多个取代基独立地选择，所述取代基包括卤素，(1-4C)烷基可选择地被一个或多个氟原子取代，(2-4C)炔基，(1-4C)烷氧基可选择性地被一个或多个氟原子取代，氨基，二(1-4C)烷基氨基，—SO2-(1-4C)烷基，—CO-(1-4C)烷基，—CO—O-(1-4C)烷基，—NH—CO-(1-4C)烷基和(3-6C)环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环，每个基都可以选择性地被(1-4C)烷基取代，单环杂环可选择性地被卤素，(1-4C)烷基或苯基取代，或双环杂环可选择性地被(1-4C)烷基取代； A从—CO—O—，—O—CO—，—NH—CO—，—CO—NH，—C═C—，—CCH3—O—和连接基—Y—(CH2)n—X—中选择，其中Y连接到R1并从键，—O—，—S—，—SO—，—SO2—，—CH2—O—，—CO—，—O—CO—，—CO—O—，—CO—NH—，—NH—CO—，—C═C—和—C≡C—中选择；n是1到10的整数；X连接到苯基/吡啶基并从键，—O—，—S—，—SO—，—SO2—，—NH，—CO—，—C═C—和—C≡C—中选择；环结构B可选择性地包含一个氮原子； R2为H，(1-4C)烷基可选择性地被一个或多个氟原子取代，(1-4C)烷氧基可选择性地被一个或多个氟原子取代，或卤素； R3为(1-4C)烷基-R5，其中烷基可以被(CH2)2取代以形成环丙基基团或一或两个卤素原子，或R3为(3-6C)环烷基-R5或—CO—CH2—R5，其中R5为—OH，—PO3H2，—OPO3H2，—COOH，—COO(1-4C)烷基或四唑-5-基； R4为H或(1-4C)烷基； R6为一个或多个取代基，独立地选择自H，(1-4C)烷基或氧代基； W为—O—，—S—，—SO—或—SO2—； 或其药学上可接受的盐、溶剂或水合物； 但是，公开的衍生物式(I)不包括2-(4-乙基苯基)-4-吗啡啶基乙醇或4-[4-(2-羟乙基)-2-吗啡啶基]苯乙腈或其药学上可接受的盐、溶剂或水合物。 本公开的化合物具有对S1P受体的亲和力，并可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS
  申请人：Iwema Bakker Wouter I.

  公开号：US20130203745A1

  公开（公告）日：2013-08-08

  The present invention relates to bisaryl(thio)morpholine derivatives of the formula (I) wherein R1 is an aryl substitutent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino, —SO 2 -(1-4C)alkyl, —CO-(1-4C)alkyl, —CO—O-(1-4C)alkyl and —NH—CO-(1-4C)alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with (1-4C)alkyl, and (8-10C)bicyclic group, bicyclic heterocycle, each optionally substituted with (1-4C)alkyl optionally substituted with one or more fluoro atoms or oxo; A is selected from —CO—, —NH—, —O—, —S—, —SO— or —SO 2 —; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R6 wherein the alkylene group may be substituted with (CH 2 ) 2 to form a cyclopropyl moiety or with one or more halogen atoms, or R3 is (3-6C)cycloalkylene-R5 or —CO—CH 2 —R6, wherein R6 is —OH, —PO 3 H 2 , —OPO 3 H 2 , —COOH, —COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R5 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is —O—, —S—, —SO— or —SO 2 —; or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula (I) is not 2-[4-(4-chlorophenoxy)-2-chloro-phenyl]-4-morpholineethanol. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本发明涉及公式（I）的双芳基（硫）吗啡啶衍生物， 其中， R1是苯基，吡啶基，嘧啶基，联苯基和萘基中选择的芳基取代基，每个取代基可以独立地选择卤素，（1-6C）烷基，可选地取代一个或多个氟原子，（1-4C）烷氧基，可选地取代一个或多个氟原子，氨基，二（1-4C）烷基氨基，—SO2-（1-4C）烷基，—CO-（1-4C）烷基，—CO—O-（1-4C）烷基和—NH—CO-（1-4C）烷基，或用苯氧基，苄基，苄氧基，苯乙基或吗啡啶基取代，每个取代基可以独立地选择（1-4C）烷基和（8-10C）双环基，双环杂环，每个取代基可以独立地选择（1-4C）烷基，可选地取代一个或多个氟原子或氧代； A选择自—CO—，—NH—，—O—，—S—，—SO—或—SO2—； 环结构B可选地含有一个氮原子； R2为H，（1-4C）烷基，可选地取代一个或多个氟原子的（1-4C）烷氧基或卤素； R3为（1-4C）烷基-R6，其中烷基可以用（CH2）2取代以形成环丙基基团或用一个或多个卤素原子取代，或者R3为（3-6C）环烷基-R5或—CO—CH2—R6，其中R6为—OH，—PO3H2，—OPO3H2，—COOH，—COO（1-4C）烷基或四唑-5-基； R4为H或（1-4C）烷基； R5为一个或多个取代基，可以独立地选择H，（1-4C）烷基或氧代； W为—O—，—S—，—SO—或—SO2—； 或其药学上可接受的盐、溶剂化合物或水合物，但公式（I）的衍生物不是2-[4-(4-氯苯氧基)-2-氯苯基]-4-吗啡啶乙醇。本发明的化合物具有亲和力S1P受体，可用于治疗、缓解或预防S1P受体介导的疾病和病情。